Epoch Investment Partners Inc. Purchases 319 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Epoch Investment Partners Inc. lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 213,498 shares of the biotechnology company’s stock after buying an additional 319 shares during the period. Epoch Investment Partners Inc. owned about 0.48% of United Therapeutics worth $49,045,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in UTHR. Norges Bank acquired a new position in United Therapeutics in the 4th quarter worth $100,519,000. Nordea Investment Management AB boosted its position in United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after acquiring an additional 262,222 shares during the last quarter. Avidity Partners Management LP acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $52,158,000. Canada Pension Plan Investment Board lifted its position in shares of United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares in the last quarter. Finally, LSV Asset Management grew its position in United Therapeutics by 40.3% in the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock valued at $121,641,000 after purchasing an additional 152,151 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR traded up $1.85 during trading hours on Friday, hitting $338.22. 290,258 shares of the company were exchanged, compared to its average volume of 439,807. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $343.98. The company has a market cap of $15.00 billion, a price-to-earnings ratio of 15.99, a P/E/G ratio of 1.48 and a beta of 0.55. The firm’s fifty day moving average is $303.01 and its 200 day moving average is $257.47.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period in the prior year, the company posted $4.86 earnings per share. On average, equities analysts anticipate that United Therapeutics Co. will post 24.94 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $258.09, for a total value of $929,124.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,551.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Insiders have sold 100,884 shares of company stock valued at $29,622,803 over the last three months. 12.50% of the stock is owned by insiders.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. HC Wainwright upped their target price on United Therapeutics from $300.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, TD Cowen raised their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $330.64.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.